ArticleThe journal of allergy and clinical immunology. Global2026
Patient perspectives of allergic rhinitis and allergen immunotherapy: A qualitative study.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [A Randomized Controlled Clinical Trial of Acupuncture at the Sphenopalatine Ganglion for the Treatment of Allergic Rhinitis].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Trial
- The Impact of Allergic Rhinitis on Australian Adults in an Urban Setting: A Qualitative Exploration.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) is a highly prevalent condition associated with significant morbidity globally. Few recent studies have detailed the experiences of sufferers and explored their perspectives of treatment options. Allergen immunotherapy (AIT) is an effective treatment option that remains underused in eligible patient populations. Objective: We sought to describe patient perspectives of AR and treatment options including AIT. Methods: Twenty-five semistructured interviews were conducted with adult participants at a tertiary hospital center in Sydney, Australia. Authors used an inductive thematic analysis methodology to code and interpret the data. Results: Three major themes emerged from the qualitative thematic analysis: (1) a prolonged journey with symptoms, (2) multiple trials of therapy with incomplete symptom control, and (3) diverse experiences with AIT. Several subthemes were identified: (1) delays to diagnosis and management, (2) underestimating the impact of symptoms, (3) substantially impaired quality of life, (4) limited efficacy of symptomatic pharmacotherapy, (5) perceptions of tolerance and dependence, (6) motivations to access AIT, (7) diverse expectations of AIT, and (8) barriers to AIT access. Conclusions: Sufferers of AR experience an impactful symptom journey, with many achieving inadequate disease control despite symptomatic pharmacotherapy. The uptake of AIT is constrained by direct medication costs, insufficient public awareness, and limited prescriber availability. The findings of this study offer insights for health care professionals and policymakers to formulate strategies to enhance AR management and improve AIT access for eligible patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.